AG0302-COVID19 / Takara, AnGes MG, Osaka University Graduate School of Medicine - LARVOL DELTA

Long Term Follow-Up Study of a Randomized, Open-Label, Uncontrolled, Phase I/II Study to Assess the Safety and Immunogenicity of Intramuscular and Intradermal Doses of COVID-19 DNA Vaccine (AG0302-COVID19). (PubMed, Vaccines (Basel)) - "The number of INF-γ-producing cells responsive to S protein increased after the first dose and was sustained for several months. AG0302-COVID-19 showed an acceptable safety profile, but the induction of a humoral immune response was insufficient to justify progressing to a Phase 3 program."

Journal • P1/2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose) (clinicaltrials.gov) - P1/2 | N=422 | Completed | Sponsor: AnGes, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Sep 2022

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Phase I Study to Assess the Safety and Immunogenicity of an Intradermal COVID-19 DNA Vaccine Administered Using a Pyro-Drive Jet Injector in Healthy Adults. (PubMed, Vaccines (Basel)) - "Overall, no notable safety issues were observed with the intradermal inoculations of AG0302-COVID19. Regarding immunogenicity, a cellular immune response was observed in some subjects after AG0302-COVID19 intradermal inoculation, but no significant antibody production was observed."

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose) (clinicaltrials.gov) - P1/2 | N=400 | Active, not recruiting | Sponsor: AnGes, Inc. | Trial primary completion date: Mar 2022 ➔ Dec 2021

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19) (clinicaltrials.gov) - P2/3 | N=500 | Completed | Sponsor: AnGes, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • IFNG

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose) (clinicaltrials.gov) - P1/2; N=400; Active, not recruiting; Sponsor: AnGes, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Study of COVID-19 DNA Vaccine (AG0302-COVID19) (clinicaltrials.gov) - P1/2; N=30; Completed; Sponsor: AnGes, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • IFNG

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose) (clinicaltrials.gov) - P1/2; N=400; Recruiting; Sponsor: AnGes, Inc.; Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose) (clinicaltrials.gov) - P1/2; N=400; Not yet recruiting; Sponsor: AnGes, Inc.

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19) (clinicaltrials.gov) - P2/3; N=500; Active, not recruiting; Sponsor: AnGes, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • IFNG

Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19) (clinicaltrials.gov) - P2/3; N=500; Recruiting; Sponsor: AnGes, Inc.

Clinical • New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • IFNG

Study of COVID-19 DNA Vaccine (AG0302-COVID19) (clinicaltrials.gov) - P1/2; N=30; Active, not recruiting; Sponsor: AnGes, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Study of COVID-19 DNA Vaccine (AG0302-COVID19) (clinicaltrials.gov) - P1/2; N=30; Recruiting; Sponsor: AnGes, Inc.

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease